RESEARCH MONOGRAPH · KDC-MN-320

Cannabidiol (CBD)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

76/100

Real pharmacology, brutally overhyped, useful as a tool compound at high purity

Look, CBD is the textbook case of a real molecule getting drowned in marketing noise. The actual pharmacology is interesting and well-mapped, and 99% of the consumer market is selling underdosed gummies that wouldnt move a behavioral assay in a rodent.

The legitimate story: CBD is a low-affinity, low-efficacy partial agonist at CB1 and CB2 with the more interesting activity sitting at non-cannabinoid targets. TRPV1 agonism. GPR55 antagonism. 5-HT1A partial agonism. Adenosine reuptake inhibition. And critically, it's an indirect endocannabinoid modulator because of FAAH inhibition that boosts endogenous anandamide tone. Mechler and Bisogno covered a lot of this in the foundational papers.

The Epidiolex approval for Dravet and Lennox-Gastaut syndromes is the real evidence anchor. Devinsky's trials showed clinically meaningful seizure reduction at high oral doses (10-20 mg/kg/day) in a population where almost nothing else works. Thats not vibes, thats good RCTs. The anxiety signal is weaker but Bergamaschi et al and some of the subsequent SAD work suggest something real at high acute doses.

What people forget: the doses that did anything in the Epidiolex trials are 1-2 orders of magnitude higher than what's in any commercially available CBD product short of medical preparations. Most of the consumer market is operating in a dose range where you'd predict essentially no effect, and the trial literature confirms that prediction.

For research: high-purity (>99%) crystalline CBD is the standard form. Sourcing has improved a lot in the last 5 years, GMP-grade material is available from multiple suppliers, HPLC/LCMS verification is straightforward. The big watch-out is residual solvents from extraction and THC content, both of which need to be QC'd.

What we like as a tool: pleiotropic at sub-micromolar concentrations, useful for FAAH-pathway work, anxiolytic models, anti-seizure assays. Good signal-to-noise in animal models at proper doses.

What we dont like is everything about the consumer market: dose-mismatched products, contamination, terrible label accuracy (multiple FDA studies have found this), and the wellness-influencer framing that papers over a serious anticonvulsant pharmacology.

Real research compound. Treat the consumer narrative as a separate problem.

Evidence: 80
Mechanism: 78
Reliability: 72
Safety: 85
Sourcing: 80
Value: 70
Signal: 65
Staying power: 78

Plain-language summary Intrigue 70 / 100

Cannabidiol is the major non-intoxicating compound in cannabis. Unlike THC it does not bind tightly to the CB1 receptor that produces a high, instead acting through a scattered network of targets (TRPV1 ion channels, GPR55, serotonin 5-HT1A, allosteric effects on CB1, fatty acid amide hydrolase inhibition). The FDA approved a purified pharmaceutical version (Epidiolex) in 2018 for three rare and severe pediatric epilepsy syndromes, where it produces meaningful seizure reduction. Beyond that approved use, the supplement market is awash with CBD products promoted for anxiety, sleep, and pain, but rigorous human evidence outside epilepsy is much thinner than the marketing implies. CBD also inhibits liver CYP3A4 and CYP2D6, creating real drug interaction risk. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phytocannabinoid (non-intoxicating)

A non-psychotomimetic phytocannabinoid from Cannabis; FDA-approved for refractory pediatric epilepsy syndromes; widely used for anxiety, sleep, and inflammation.

Abstract

Cannabidiol (CBD; CAS 13956-29-1; molecular formula C21H30O2; molecular weight 314.46) is the principal non-intoxicating phytocannabinoid of Cannabis sativa, approved by the FDA in 2018 as Epidiolex for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex-associated seizures. Mechanism is multifactorial and incompletely characterized: minimal CB1 affinity (avoiding the THC-like psychoactivity), CB2 partial agonism, allosteric CB1 negative modulation (potentially attenuating THC effects), TRPV1 agonism, GPR55 antagonism, 5-HT1A partial agonism, and inhibition of fatty acid amide hydrolase (raising endogenous anandamide). Plasma half-life is 18 to 32 hours; metabolism is via CYP3A4 and CYP2C19, with CBD itself being a moderate inhibitor of CYP3A4 and CYP2D6 producing clinically relevant drug-drug interactions. Approved indications: refractory pediatric epilepsy. Off-label use is extensive (anxiety, sleep, pain, inflammation) with mixed clinical evidence and substantial product variability in the consumer market. Used as the canonical non-intoxicating phytocannabinoid in research.

Mechanism of action

Multifactorial: weak CB1, CB2 partial agonism, allosteric CB1 modulation, TRPV1, GPR55, 5-HT1A, FAAH inhibition. CYP3A4 and CYP2D6 inhibition.

Reported research dose ranges

Clinical 5 to 25 mg/kg in the published literature (Epidiolex). Supplement use 25 to 1000 mg.

References

Devinsky O, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017.
Ibeas Bih C, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 2015.
Bonn-Miller MO, et al. Labeling accuracy of cannabidiol extracts sold online. JAMA 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-320

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Cannabidiol (CBD)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs